Comparative in vitro activity of carbapenems against major Gram-negative pathogens: Results of Asia-Pacific surveillance from the COMPACT II study

International Journal of Antimicrobial Agents

Volumn 39, Issue 4, 2012, Pages 311-316

  Kiratisin, Pattarachai ^a   Chongthaleong, Anan ^b   Tan, Thean Yen ^c   Lagamayo, Evelina ^d   Roberts, Sally ^e   Garcia, Jemelyn ^f   Davies, Todd ^g  

^a MAHIDOL UNIVERSITY   (Thailand)

^b KING CHULALONGKORN MEMORIAL HOSPITAL   (Thailand)

^c CHANGI GENERAL HOSPITAL   (Singapore)

^d St Luke's Medical Centre   (Philippines)

^e AUCKLAND CITY HOSPITAL   (New Zealand)

^f JOHNSON AND JOHNSON   (United States)

^g JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Acinetobacter; Carbapenem; Enterobacteriaceae; Gram negative bacteria; Pseudomonas; Surveillance

Indexed keywords

CARBAPENEM; DORIPENEM; EXTENDED SPECTRUM BETA LACTAMASE; IMIPENEM; MEROPENEM;

ACINETOBACTER BAUMANNII; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL PERITONITIS; BACTERIAL PNEUMONIA; BACTERIUM ISOLATE; BIOSURVEILLANCE; BLOODSTREAM INFECTION; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENCY; ENTEROBACTERIACEAE; GRAM NEGATIVE BACTERIUM; HOSPITAL INFECTION; HUMAN; IN VITRO STUDY; INFECTION CONTROL; MINIMUM INHIBITORY CONCENTRATION; NEW ZEALAND; NONHUMAN; PHILIPPINES; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; SINGAPORE; THAILAND; VENTILATOR ASSOCIATED PNEUMONIA; VIET NAM;

ANTI-BACTERIAL AGENTS; ASIA; BETA-LACTAMASES; CARBAPENEMS; CROSS INFECTION; DRUG RESISTANCE, MULTIPLE, BACTERIAL; GEOGRAPHY; GRAM-NEGATIVE BACTERIA; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; INHIBITORY CONCENTRATION 50; INTENSIVE CARE UNITS; MICROBIAL SENSITIVITY TESTS; PACIFIC ISLANDS; POPULATION SURVEILLANCE; PREVALENCE;

EID: 84863412135     PISSN: 09248579     EISSN: 18727913     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2012.01.002     Document Type: Article

References (27)

1. Chen YH, Hsueh PR, Badal RE, Hawser SP, Hoban DJ, Bouchillon SK, et al. Antimicrobial susceptibility profiles of aerobic and facultative Gram-negative bacilli isolated from patients with intra-abdominal infections in the Asia-Pacific region according to currently established susceptibility interpretive criteria. J Infect 2011;62:280-91.
2. Slama TG. Gram-negative antibiotic resistance: there is a price to pay. Crit Care 2008;12(Suppl. 4):S4.
3. US Centers for Disease Control and Prevention. A public health action plan to combat antimicrobial resistance. http://www.cdc.gov/drugresistance/ actionplan/taskforce.html [accessed 6 May 2011].
4. Infectious Diseases Society of America (IDSA), Spellberg B, Blaser M, Guidos RJ, Boucher HW, Bradley JS, et al. Combating antimicrobial resistance: policy recommendations to save lives. Clin Infect Dis 2011;52(Suppl. 5):S397-428.
5. World Health Organization. WHO global strategy for the containment of antimicrobial resistance. Geneva, Switzerland: WHO; 2001, http://www.who.int/ drugresistance/guidance/en/index.html [accessed 6 May 2011].
6. Song JH, Asian Hospital Acquired Pneumonia Working Group. Treatment recommendations of hospital-acquired pneumonia in Asian countries: first consensus report by the Asian HAP Working Group. Am J Infect Control 2008;36(4 Suppl.):S83-92.
7. Chawla R. Epidemiology, etiology, and diagnosis of hospital-acquired pneumonia and ventilator-associated pneumonia in Asian countries. Am J Infect Control 2008;36(4 Suppl.):S93-100.
8. Bouchillon SK, Iredell JR, Barkham T, Lee K, Dowzicky MJ. Comparative in vitro activity of tigecycline and other antimicrobials against Gram-negative and Gram-positive organisms collected from the Asia-Pacific Rim as part of the Tigecycline Evaluation and Surveillance Trial (TEST). Int J Antimicrob Agents 2009;33:130-6.
9. Lagamayo EN. Antimicrobial resistance in major pathogens of hospital-acquired pneumonia in Asian countries. Am J Infect Control 2008;36(4 Suppl.):S101-8. (Pubitemid 351632965)
10. Lee NY, Lee HC, Ko NY, Chang CM, Shih HI, Wu CJ, et al. Clinical and economic impact of multidrug resistance in nosocomial Acinetobacter baumannii bacteremia. Infect Control Hosp Epidemiol 2007;28:713-19.
11. Schwaber MJ, Navon-Venezia S, Kaye KS, Ben-Ami R, Schwartz D, Carmeli Y. Clinical and economic impact of bacteremia with extended-spectrum- β-lactamase-producing Enterobacteriaceae. Antimicrob Agents Chemother 2006;50:1257-62.
12. Paterson DL, Ko WC, Von Gottberg A, Mohapatra S, Casellas JM, Goossens H, et al. Antibiotic therapy for Klebsiella pneumoniae bacteremia: implications of production of extended-spectrum β-lactamases. Clin Infect Dis 2004;39: 31-7. (Pubitemid 38879546)
13. American Thoracic Society, Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005;171:388-416.
14. Nicolau DP. Carbapenems: a potent class of antibiotics. Expert Opin Pharmacother 2008;9:23-37. (Pubitemid 351233746)
15. Pillar CM, Torres MK, Brown NP, Shah D, Sahm DF. In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by Gram-negative bacteria, against recent clinical isolates from the United States. Antimicrob Agents Chemother 2008;52:4388-99.
16. Nicholson SC, Petersen JA. Doripenem, a new carbapenem: optimizing dose to treat increasingly resistant Gram-negative pathogens. In: Program and abstracts of the 2nd World Conference on Magic Bullets (EHRLICH II). 2008 [Abstract A-229].
17. Samtani MN, Flamm R, Kaniga K, Nandy P. Pharmacokinetic-pharmacodynamic- model-guided doripenem dosing in critically ill patients. Antimicrob Agents Chemother 2010;54:2360-4.
18. Christiansen KJ, Ip M, Ker HB, Mendoza M, Hsu L, Kiratisin P, et al. In vitro activity of doripenem and other carbapenems against contemporary Gram-negative pathogens isolated from hospitalised patients in the Asia-Pacific region: results of the COMPACT Asia-Pacific Study. Int J Antimicrob Agents 2010;36:501-6.
19. Clinical and Laboratory Standards Institute. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard. Document M07-A8. 8th ed. Wayne, PA: CLSI; 2009.
20. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; twentieth informational supplement. Document M100-S20. Wayne, PA: CLSI; 2010.
21. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; nineteenth informational supplement (June 2010 update). Document M100-S20-U. Wayne, PA: CLSI; 2010.
22. Jean SS, Hsueh PR. High burden of antimicrobial resistance in Asia. Int J Antimicrob Agents 2011;37:291-5.
23. Talbot GH, Bradley J, Edwards Jr JE, Gilbert D, Scheld M, Barlett JG. Bad bugs need drugs: an update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America. Clin Infect Dis 2006;42:657-68. (Pubitemid 43271379)
24. Davies TA, Marie Queenan A, Morrow BJ, Shang W, Amsler K, He W, et al. Longitudinal survey of carbapenem resistance and resistance mechanisms in Enterobacteriaceae and non-fermenters from the USA in 2007-09. J Antimicrob Chemother 2011;66:2298-307.
25. Hsueh PR, Badal RE, Hawser SP, Hoban DJ, Bouchillon SK, Ni Y, et al. Epidemiology and antimicrobial susceptibility profiles of aerobic and facultative Gram-negative bacilli isolated from patients with intra-abdominal infections in the Asia-Pacific region: 2008 results from SMART (Study for Monitoring Antimicrobial Resistance Trends). Int J Antimicrob Agents 2010;36:408-14.
26. Roberts JA, Lipman J. Pharmacokinetic issues for antibiotics in the critically ill patient. Crit Care Med 2009;37:840-51.
27. Kaki R, Elligsen M, Walker S, Simor A, Palmay L, Daneman N. Impact of antimicrobial stewardship in critical care: a systematic review. J Antimicrob Chemother 2011;66:1223-30.